Product Name: Lyn (16-34)
Product Number: PE-01BDP80
Size: 200 µg      Price:48.00
1 mg      $US96.00
5 mg      208.00
Peptide Name: Lyn (16-34)

Product Use: Services as a blocking peptide for use with the Lyn-ANT rabbit polyclonal antibody (Cat. No.: AB-NK095-2) that is also available from Kinexus. The peptide sequence is located in the post-N-terminus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CGVDLKTQPVRNTERTIYVR

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 2347.7 Da

Peptide Purity Percent after Synthesis and Purification: >80

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: Lyn pan-specific antibody (Cat. No.: AB-NK095-2)

Scientific Background: Lyn is a protein-tyrosine kinase of the TK group and Src family. It is important in signal transduction from cell surface receptors and in the regulation of innate and adaptive immune responses and other cellular functions. Phosphorylation of T503 inhibits its phosphotransferase activity.This kinase is highly expressed and widely distributed in most tested human tissues. Lyn deficiency is involved in defects in some mast cell functions. It interacts with phosphorylated LIME1 and with CD79A upon BCR activation. Lyn is inhibited by phosphorylation at T503. It interacts with a variety of cell surface receptors on the cytoplasmic side of the plasma membrane. Lyn is biosynthetically transported to the plasma membrane via the Golgi pool of caveolin along the secretory pathway that requires its catalytic domain, but not activity. Lyn is expressed preferentially in B cells and can be bound in the plasma membrane with IgM, where it participates in antigen-mediated signal transduction. Crosslinking of membrane-bound IgM with antibody induces rapid increase in activities of Lyn and Lyn-associated PI 3-kinase. Lyn may be involved in the changes that are related to tumour pathogenesis. It is constitutively phosphorylated and activated in cells of chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) patients. Abnormally enhanced expression levels of activation of Lyn signalling can be critical in survival and proliferation of some types of cancers, inclduing breast carcinomas.